Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB-201 for Arterial Inflammation in Treated HIV
NCT04939311Phase 2Withdrawn
- Start
- Jul 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in arteritis comparing VB-201 with Placebo (2 arms). Primary endpoint: Change in Target-to-background ratio at 1 year. Planned start Jul 2022; status: withdrawn.
02
Drugs
VB-201
03
Conditions
arteritis
Beyond the preview
Go deeper on NCT04939311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939311.